Disulfiram

Sold as Antabuse. Every FDA application for this active ingredient: 1 branded and 13 generic.

As of Nov 15, 2026, FDA lists 14 applications for Disulfiram (sold as Antabuse), first approved Aug 28, 1951, with 0 new uses approved and 0 published complete response letters.

First approved: Aug 28, 1951
Applications: 14
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $2.7M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Disulfiram	Part D	$2.7M	+21%	8,727

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

DISULFIRAM 250 MG TABLET: $1.75 per unitGeneric · 0% in a year
DISULFIRAM 500 MG TABLET: $13.21 per unitGeneric · -1% in a year

Clinical Trials

13 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma · University of Michigan Rogel Cancer Center	Phase 1 / Phase 2	Not yet recruiting	Nov 12, 2026
MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label StudyThoracic Cancer · M.D. Anderson Cancer Center	Phase 2	Not yet recruiting	Sep 28, 2026
Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High Grade GliomaBrain (Nervous System) Cancers · Case Comprehensive Cancer Center	Phase 1	Not yet recruiting	Jul 22, 2026
Disulfiram in Rheumatoid ArthritisRheumatoid Arthritis, Inflammation · University of Oklahoma	Phase 2	Not yet recruiting	Apr 16, 2026
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaOsteosarcoma, Metastasis · Memorial Sloan Kettering Cancer Center	Phase 2	Recruiting	Mar 17, 2026
Anxiety During Abstinence in AUDAlcohol Use Disorder · Columbia University	Early phase 1	Recruiting	Jan 27, 2025
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal DegenerationAlcohol Use Disorder, Retinal Dystrophies · University of Rochester	Phase 1	Recruiting	Mar 20, 2024
Combining a Smartphone App With Medications to Manage Heavy DrinkingAlcohol Use Disorder (AUD) · VA Office of Research and Development	Not applicable	Recruiting	Mar 12, 2024

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Aug 28, 1951	AntabuseNDA 7883 · New molecular entity	Teva Womens	18	Discontinued
Mar 31, 1981	DisulfiramANDA 86889	Watson Labs	11	Discontinued
Mar 31, 1981	DisulfiramANDA 86890	Watson Labs Teva	11	Discontinued
Aug 5, 1983	DisulfiramANDA 87973	Watson Labs	0	Discontinued
Aug 5, 1983	DisulfiramANDA 87974	Watson Labs	0	Discontinued
Dec 8, 1983	AntabuseANDA 88482	Odyssey Pharms	18	Discontinued
Dec 8, 1983	AntabuseANDA 88483	Odyssey Pharms	10	Discontinued
Aug 14, 1984	DisulfiramANDA 88792	Strides Pharma Intl	6	Discontinued
Aug 14, 1984	DisulfiramANDA 88793	Strides Pharma Intl	6	Discontinued
Mar 28, 2011	DisulfiramANDA 91619	Sigmapharm Labs LLC	1	Marketed
Dec 31, 2012	DisulfiramANDA 91563	Chartwell Molecules	1	Marketed
Aug 8, 2013	DisulfiramANDA 91681	Alvogen	0	Marketed
Feb 5, 2014	DisulfiramANDA 202652	Hikma	0	Discontinued
Mar 4, 2015	DisulfiramANDA 203916	Natco Pharma USA	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA